1van Voorhis WC, Barrett LK, Eastman RT, et al. Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrobiol Agents Chemother, 2003,47 (2): 475
2Lin L,Corten L, Murthy KK,et al. Photochemical inactivation of hepatitis B (HBV) and hepatitis C (HCV) virus in human platelet concentrates as assessed by a chimpanzee infectivity model. Blood, 1998,92 (10) S1: 502a
3Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol,2001,38(4 Suppl 11):4
4Hei DJ, Grass J, Lin L, et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion,1999,39(3): 239
5Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood,1998,91(6):2180
6Grass JA, Wafa T, Reames A, et al. Prevention of transfusionassociated graft-versus-host disease by photochemical treatment. Blood,1999,93(9) :3140
7Ciaravi V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated)platelets. Hum Exp Toxicol, 2001,20(10): 533
8van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood,2003,101(6) :2426
9Wu YY, Snyder EL. Safety of the blood supply: role of pathogen reduction. Blood Rev, 2003,17(2) : 111
10Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion, 1997,37(4) :423
同被引文献17
1Nishizawa T, okamoto H, Konishi K, et al. A novel DNA Virus (TTV)associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology [ J ]. Bichem Biophys Rescommun, 1997,24 ( 1 ) : 92 -93.
2Busch MP, KeinmanSH, Jackson B, et al. Nucleic acid amplification testing of blood donors for transfusion transmitted infectious diseases. Report of interorganizational force on nucleic acid amplification testing of blood donors [ J ]. Transfusion, 2000,40 ( 2 ) : 143-159.
3Vasconcelos E, Seghatchian J. Bacterial contamination in blood components and preventative strategies : an overview [ J ]. Transfus Apheresis Sci ,2004,31 (2) : 155-163.
4Dhingra N, Lloyd SE, Fordham J, et al. Challenges in global blood safety[J]. World Hosp Health Serv,2004,40( 1 ) :45-52.
5McDonald CP, Lowe P, Roy A, et al. Evaluation of donor ann disinfection techniques[J]. Vox Sang,2001,80(3 ) :135-141.
9Jackson BR, Busch MP, Strainer SL,et al. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations[ J]. Transfusion,2003,43 ( 6 ) :721-729.
10Wakimono N. Current situation and issues of preoperative autologous blood donation in Tapen [ J ]. Nippon Geka Gakkai Zasshi, 2005,106( 1 ) :23-30.
